These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17485587)

  • 1. Letter by Kielstein et al regarding article, "High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid".
    Kielstein JT; Woywodt A; Salpeter SR
    Circulation; 2007 May; 115(18):e450-1; author reply e451. PubMed ID: 17485587
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.
    George J; Carr E; Davies J; Belch JJ; Struthers A
    Circulation; 2006 Dec; 114(23):2508-16. PubMed ID: 17130343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
    Panomvana D; Sripradit S; Angthararak S
    J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies with allopurinol in patients with impaired renal function.
    Elion GB; Benezra FM; Beardmore TD; Kelley WN
    Adv Exp Med Biol; 1980; 122A():263-7. PubMed ID: 7424645
    [No Abstract]   [Full Text] [Related]  

  • 5. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.
    Dalbeth N; Stamp L
    Semin Dial; 2007; 20(5):391-5. PubMed ID: 17897242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of allopurinol in patients with hypoxanthine-guanine phosphoribosyltransferase deficiency.
    Torres RJ; Prior C; Puig JG
    Metabolism; 2007 Sep; 56(9):1179-86. PubMed ID: 17697859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal clearances of purine bases and oxypurinol during glucose infusion.
    Moriwaki Y; Yamamoto T; Takahashi S; Nasako Y; Hada T; Higashino K
    Adv Exp Med Biol; 1994; 370():39-42. PubMed ID: 7660935
    [No Abstract]   [Full Text] [Related]  

  • 8. Inflammation in chronic heart failure.
    Parish RC; Evans JD
    Ann Pharmacother; 2008 Jul; 42(7):1002-16. PubMed ID: 18477736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose allopurinol in patients with stable angina pectoris.
    Kielstein JT; Schmidt BM
    Lancet; 2010 Oct; 376(9749):1298-9; author reply 1299-300. PubMed ID: 20951884
    [No Abstract]   [Full Text] [Related]  

  • 10. Absorption and metabolism of allopurinol and oxypurinol by rat jejunum in vitro: effects on uric acid transport.
    Shaw MI; Parsons DS
    Clin Sci (Lond); 1984 Mar; 66(3):257-67. PubMed ID: 6692658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal venous congestion and renal function in congestive heart failure.
    Joles JA; Bongartz LG; Gaillard CA; Braam B
    J Am Coll Cardiol; 2009 Oct; 54(17):1632; author reply 1632-3. PubMed ID: 19833266
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
    Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
    Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of osmadizone on serum uric acid as well as on renal uric acid, oxypurine and orotic acid excretion in healthy subjects].
    Gröbner W; Meurer M; Zöllner N
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1527-9. PubMed ID: 1030038
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter by Andreotti et al regarding article, "Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) study".
    Andreotti F; Coluzzi G; Crea F
    Circulation; 2007 Mar; 115(9):e313; author reply e314. PubMed ID: 17339559
    [No Abstract]   [Full Text] [Related]  

  • 15. Uric acid--a bad acid for the kidney?
    Dharnidharka VR; Johnson RJ
    Pediatr Transplant; 2008 Dec; 12(8):821-2. PubMed ID: 18503480
    [No Abstract]   [Full Text] [Related]  

  • 16. Non-responsiveness to allopurinol in renal hypouricaemia.
    Löffler W; Seibke W; Seibke E; Reiter S; Jahn M; Hehlmann R; Zöllner N
    Klin Wochenschr; 1989 Jan; 67(1):47. PubMed ID: 2921842
    [No Abstract]   [Full Text] [Related]  

  • 17. The allopurinol hypersensitivity syndrome: its relation to plasma oxypurinol levels.
    Casas E; Puig JG; Mateos FA; Jiménez ML; Michán AD; Ramos TH
    Adv Exp Med Biol; 1989; 253A():257-60. PubMed ID: 2624201
    [No Abstract]   [Full Text] [Related]  

  • 18. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The beneficial effects of allopurinol in cardiology practice: decrease in uric acid and vascular oxidative stress/ the effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study.
    Yiğiner O; Ozçelik F; Aparci M; Işilak Z; Uz O
    Anadolu Kardiyol Derg; 2010 Jun; 10(3):294-5; author reply 295-6. PubMed ID: 20538573
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting the kidney in acute decompensated heart failure: conventional diuretics and renal-acting vasodilators.
    Martin FL; Chen HH; Cataliotti A; Burnett JC
    Rev Cardiovasc Med; 2008; 9(1):39-45. PubMed ID: 18418308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.